Theaflavins suppress tumor growth and metastasis via the blockage of the STAT3 pathway in hepatocellular carcinoma

OncoTargets and Therapy

Volumn 9, Issue , 2016, Pages 4265-4275

  Shao, Jianping ^a   Meng, Qingyan ^a   Li, Yongyuan ^a  

^a TIANJIN FIFTH CENTRAL HOSPITAL   (China)

Author keywords

Hepatocellular carcinoma; STAT3; Theaflavins; Tumor growth; Tumor metastasis

Indexed keywords

CASPASE 3; CASPASE 9; CASPASE INHIBITOR; GELATINASE A; GELATINASE B; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; STAT3 PROTEIN; SURVIVIN; THEAFLAVIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IC50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CANCER CELL LINE; LIVER CELL CARCINOMA; LUNG METASTASIS; MALE; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TREATMENT DURATION; TUMOR VOLUME; TUNEL ASSAY;

EID: 84978697997     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S102858     Document Type: Article

References (31)

1. Singal AG, El-Serag HB. Hepatocellular carcinoma from epidemiology to prevention: translating knowledge into practice. Clin Gastroenterol Hepatol. 2015;13(12):2140-2151.
2. Lee JS, Thorgeirsson SS. Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets. Gastroenterology. 2004;127(5 Suppl 1):S51-S55.
3. Thorgeirsson SS, Lee JS, Grisham JW. Molecular prognostication of liver cancer: end of the beginning. J Hepatol. 2006;44(4):798-805.
4. Cervello M, McCubrey JA, Cusimano A, Lampiasi N, Azzolina A, Montalto G. Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget. 2012;3(3):236-260.
5. Clardy J, Walsh C. Lessons from natural molecules. Nature. 2004;432(7019):829-837.
6. Tanaka T, Inoue K, Betsumiya Y, Mine C, Kouno I. Two types of oxidative dimerization of the black tea polyphenol theaflavin. J Agric Food Chem. 2001;49(12):5785-5789.
7. Leung LK, Su Y, Chen R, Zhang Z, Huang Y, Chen ZY. Theaflavins in black tea and catechins in green tea are equally effective antioxidants. J Nutr. 2001;131(9):2248-2251.
8. Hasaniya N, Youn K, Xu M, Hernaez J, Dashwood R. Inhibitory activity of green and black tea in a free radical-generating system using 2-amino-3-methylimidazo[4,5-f]quinoline as substrate. Jpn J Cancer Res. 1997;88(6):553-558.
9. Shiraki M, Hara Y, Osawa T, Kumon H, Nakayama T, Kawakishi S. Antioxidative and antimutagenic effects of theaflavins from black tea. Mutat Res. 1994;323(1-2):29-34.
10. Lahiry L, Saha B, Chakraborty J, et al. Theaflavins target Fas/caspase-8 and Akt/pBad pathways to induce apoptosis in p53-mutated human breast cancer cells. Carcinogenesis. 2010;31(2):259-268.
11. Adhikary A, Mohanty S, Lahiry L, Hossain DM, Chakraborty S, Das T. Theaflavins retard human breast cancer cell migration by inhibiting NF-kappaB via p53-ROS cross-talk. FEBS Lett. 2010;584(1):7-14.
12. Prasad S, Kaur J, Roy P, Kalra N, Shukla Y. Theaflavins induce G2/M arrest by modulating expression of p21waf1/cip1, cdc25C and cyclin B in human prostate carcinoma PC-3 cells. Life Sci. 2007;81(17-18):1323-1331.
13. Sun S, Pan S, Miao A, et al. Active extracts of black tea (Camellia Sinensis) induce apoptosis of PC-3 prostate cancer cells via mitochondrial dysfunction. Oncol Rep. 2013;30(2):763-772.
14. Sil H, Sen T, Moulik S, Chatterjee A. Black tea polyphenol (theaflavin) downregulates MMP-2 in human melanoma cell line A375 by involving multiple regulatory molecules. J Environ Pathol Toxicol Oncol. 2010;29(1):55-68.
15. Lahiry L, Saha B, Chakraborty J, et al. Contribution of p53-mediated Bax transactivation in theaflavin-induced mammary epithelial carcinoma cell apoptosis. Apoptosis. 2008;13(6):771-781.
16. Weerawatanakorn M, Lee YL, Tsai CY, et al. Protective effect of theaflavin-enriched black tea extracts against dimethylnitrosamine-induced liver fibrosis in rats. Food Funct. 2015;6(6):1832-1840.
17. Yang CS, Wang ZY. Tea and cancer. J Natl Cancer Inst. 1993;85(13):1038-1049.
18. Chai EZ, Shanmugam MK, Arfuso F, et al. Targeting transcription factor STAT3 for cancer prevention and therapy. Pharmacol Ther. 2016;162:86-97.
19. Schuringa JJ, Wierenga AT, Kruijer W, Vellenga E. Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. Blood. 2000;95(12):3765-3770.
20. Zhong Z, Wen Z, Darnell JE Jr. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science. 1994;264(5155):95-98.
21. Hemmann U, Gerhartz C, Heesel B, et al. Differential activation of acute phase response factor/Stat3 and Stat1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. II. Src homology SH2 domains define the specificity of stat factor activation. J Biol Chem. 1996;271(22):12999-13007.
22. Lai PS, Rosa DA, Magdy Ali A, et al. A STAT inhibitor patent review: progress since 2011. Expert Opin Ther Pat. 2015;25(12):1397-1421.
23. Peyser ND, Grandis JR. Critical analysis of the potential for targeting STAT3 in human malignancy. Onco Targets Ther. 2013;6:999-1010.
24. Shodeinde AL, Barton BE. Potential use of STAT3 inhibitors in targeted prostate cancer therapy: future prospects. Onco Targets Ther. 2012;5:119-125.
25. Zuo M, Li C, Lin J, Javle M. LLL12, a novel small inhibitor targeting STAT3 for hepatocellular carcinoma therapy. Oncotarget. 2015;6(13):10940-10949.
26. Subramaniam A, Shanmugam MK, Ong TH, et al. Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3. Br J Pharmacol. 2013;170(4):807-821.
27. Rajendran P, Li F, Manu KA, et al. γ-Tocotrienol is a novel inhibitor of constitutive and inducible STAT3 signalling pathway in human hepatocellular carcinoma: potential role as an antiproliferative, pro-apoptotic and chemosensitizing agent. Br J Pharmacol. 2011;163(2):283-298.
28. Liu Y, Liu A, Xu Z, et al. XZH-5 inhibits STAT3 phosphorylation and causes apoptosis in human hepatocellular carcinoma cells. Apoptosis. 2011;16(5):502-510.
29. Yoshida T, Hanada T, Tokuhisa T, et al. Activation of STAT3 by the hepatitis C virus core protein leads to cellular transformation. J Exp Med. 2002;196(5):641-653.
30. Subramaniam A, Shanmugam MK, Perumal E, et al. Potential role of signal transducer and activator of transcription (STAT)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma. Biochim Biophys Acta. 2013;1835(1):46-60.
31. Bhattacharya U, Halder B, Mukhopadhyay S, Giri AK. Role of oxidation-triggered activation of JNK and p38 MAPK in black tea polyphenols induced apoptotic death of A375 cells. Cancer Sci. 2009;100(10):1971-1978.